TSX · EPRX.TO
Eupraxia Pharmaceuticals Inc.
CA$10.14-CA$0.14 (-1.36%)
Eupraxia Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 22.48% below the high.
Loading market information…
TSX · PRN.TO · CAD
Stock price, earnings
Quote as of Oct 29, 2026, 07:58 PM UTC. Cached market data; not a live quote.
One-year closing-price history · CAD. Historical prices are not a forecast.
Profound Medical Corp.’s quoted price sits in the lower half of its reported 52-week range, 33.79% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Profound Medical Corp.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -CA$0.27. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Profound Medical Corp.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Profound Medical Corp., along with its subsidiaries, operates as a commercial-stage medical technology firm. The company specializes in creating magnetic resonance (MR) guided ablation therapies designed to address prostate conditions, uterine fibroids, and to provide palliative pain management. Its market reach extends to Canada, Germany, the United States, and Finland. The company's primary offering is the TULSA-PRO system, which is engineered to integrate with magnetic resonance imaging (MRI) scanners within hospitals and clinical treatment facilities. Additionally, Profound Medical offers Sonalleve, a versatile therapeutic platform that treats uterine fibroids, delivers palliative pain relief for bone metastases, and provides non-invasive solutions for uterine fibroid treatment. Profound Medical Corp. maintains its corporate headquarters in Mississauga, Canada.
Latest available per-share figures in CAD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:28 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 8, 2025 | -CA$0.52-27.43% vs estimate | CA$3.77M-21.17% vs estimate |
|---|
| Q4 2024 | Mar 6, 2025 | -CA$0.29+31.47% vs estimate | CA$6.01M-1.14% vs estimate |
|---|
| Q3 2024 | Nov 7, 2024 | -CA$0.51-26.66% vs estimate | CA$3.83M-5.74% vs estimate |
|---|
THE ANALYST VIEW
7 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CA$10.14-CA$0.14 (-1.36%)
Eupraxia Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 22.48% below the high.
CA$5.15+CA$0.15 (+3.0%)
NervGen Pharma Corp.’s quoted price sits in the lower half of its reported 52-week range, 39.34% below the high.
CA$3.67+CA$0.09 (+2.51%)
Auxly Cannabis Group Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.13% below the high.
CA$15.01-CA$0.21 (-1.38%)
Cybin Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.42% below the high.
CA$14.70+CA$0.03 (+0.2%)
Medical Facilities Corporation’s quoted price sits in the lower half of its reported 52-week range, 21.77% below the high.
CA$4.98+CA$0.02 (+0.4%)
Quipt Home Medical Corp.’s quoted price sits in the upper half of its reported 52-week range, 0.4% below the high.
CA$3.32-CA$0.02 (-0.6%)
CareRx Corporation’s quoted price sits in the lower half of its reported 52-week range, 17.0% below the high.
$0.53+$0.01 (+2.72%)
Jushi Holdings Inc’s quoted price sits in the lower half of its reported 52-week range, 41.69% below the high.
